[Cancer Management and Research] Researchers present a simple classification method for assessing fatigue, which is proven to be a prognostic marker of TTP and OS in patients with HCC.
In the CRL, the FDA stated that the data from KEYNOTE-524/Study 116 did not demonstrate a meaningful advantage over available therapies for unresectable or metastatic HCC.
[Cancer Management and Research] Researchers sought to determine if apatinib-related hypertension was a predictor of drug efficacy in patients with advanced HCC.
The FDA has approved Tecentriq® in combination with Avastin® for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
The combination resulted in durable response in many patients.